Ovid Therapeutics (OVID) EBT Margin (2020 - 2025)
Ovid Therapeutics (OVID) reported EBT Margin of 1345.82% for Q4 2025, up 1352082.0% on a YoY basis from N/an in Q4 2024, and up 114.61% quarter-over-quarter from 9210.61% in Q3 2025.
Ovid Therapeutics (OVID) EBT Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics has reported EBT Margin for 6 years, with the latest figure at 1345.82% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin rose 1352082.0% year-over-year to 1345.82%; the trailing twelve-month figure through Mar 2026 stood at 339.33% (up 421779.0% YoY), and the FY2025 full-year result was 240.13%, up 443001.0% from the prior year.
- EBT Margin for Q4 2025 stood at 1345.82%, up from 9210.61% in the prior quarter.
- The five-year high for EBT Margin was 5042.01% in Q2 2024, with the low at 107798.33% in Q3 2022.
- Historically, EBT Margin has averaged 14449.63% across 5 years, with a median of 8653.28% in 2024.
- The largest YoY upside for EBT Margin was 9747448 bps in 2023 against a maximum downside of 1845214 bps in 2023.
- Ovid Therapeutics' EBT Margin stood at 84.7% in 2021, then sank by 29448 bps to 24859.09% in 2022, then jumped by 57 bps to 10790.14% in 2023, then retreated by 13 bps to 12175.0% in 2024, then jumped by 111 bps to 1345.82% in 2025.
- The last three EBT Margin figures came in at 1345.82% (Q4 2025), 9210.61% (Q3 2025), and 74.68% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,345.82% |
| Sep 30, 2025 | -9,210.61% |
| Jun 30, 2025 | -74.68% |
| Mar 31, 2025 | -7,873.08% |
| Dec 31, 2024 | -12,175.00% |
| Sep 30, 2024 | -8,095.95% |
| Jun 30, 2024 | 5,042.01% |
| Mar 31, 2024 | -7,901.35% |
| Dec 31, 2023 | -10,790.14% |
| Sep 30, 2023 | -10,323.85% |
| Jun 30, 2023 | -16,544.00% |
| Mar 31, 2023 | -20,236.36% |
| Dec 31, 2022 | -24,859.09% |
| Sep 30, 2022 | -107,798.33% |
| Mar 31, 2022 | -1,784.23% |
| Mar 31, 2021 | 84.70% |
| Dec 31, 2020 | -386.27% |
| Sep 30, 2020 | -237.56% |